Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D2 and D3 dopamine receptors

Journal of Neuroscience Methods

Volumn 188, Issue 1, 2010, Pages 32-38

  Zhen, Juan ^a   Antonio, Tamara ^a   Dutta, Aloke K ^b   Reith, Maarten E A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Competition inhibition curve; Dopamine receptor; High affinity binding assay; Receptor concentration; Spiperone

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; RADIOLIGAND; ROPINIROLE; SPIPERONE DERIVATIVE; SPIPERONE H 3; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BINDING AFFINITY; CHENG PRUSOFF EQUATION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IC 50; LIGAND BINDING; MATHEMATICAL PARAMETERS; PRIORITY JOURNAL; SIMULATION; THEORETICAL STUDY;

BINDING, COMPETITIVE; CELL LINE; COMPUTER SIMULATION; DOPAMINE ANTAGONISTS; HUMANS; KIDNEY; MODELS, BIOLOGICAL; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SPIPERONE; TRITIUM;

EID: 77950459900     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.01.031     Document Type: Article

References (26)

1. Bennett J.P., Yamamura H.I. Neurotransmitter, hormone, or drug receptor binding methods. Neurotransmitter receptor binding 1985, 61-89. Raven Press, New York. 2nd ed. H.I. Yamamura, S.J. Enna, M.J. Kuhar (Eds.).
2. Chang K.J., Jacobs S., Cuatrecasas P. Quantitative aspects of hormone-receptor interactions of high affinity. Effect of receptor concentration and measurement of dissociation constants of labeled and unlabeled hormones. Biochim. Biophys. Acta 1975, 406:294-303.
3. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22:3099-3108.
4. Chio C.L., Lajiness M.E., Huff R.M. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol. Pharmacol. 1994, 45:51-60.
5. Dutta A.K., Fei X.S., Reith M.E. A novel series of hybrid compounds derived by combining 2-aminotetralin and piperazine fragments: binding activity at D2 and D3 receptors. Bioorg. Med. Chem. Lett. 2002, 12:619-622.
6. Gardner B., Hall D.A., Strange P.G. Pharmacological analysis of dopamine stimulation of [35S]-GTP gamma S binding via human D2short and D2long dopamine receptors expressed in recombinant cells. Br. J. Pharmacol. 1996, 118:1544-1550.
7. Girault J.A., Greengard P. The neurobiology of dopamine signaling. Arch. Neurol. 2004, 61:641-644.
8. Jacobs S., Chang K.-J., Cuatrecasas P. Estimation of hormone receptor affinity by competitive displacement of labeled ligand: effect of concentration of receptor and of labeled ligand. Biochem. Biophys. Res. Commun. 1975, 66:687-692.
9. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 1997, 49:231-252.
10. Linden J. Calculating the dissociation constant of an unlabeled compound from the concentration required to displace radiolabel binding by 50%. J. Cyclic. Nucleotide. Res. 1982, 8:163-172.
11. Lundstrom K., Turpin M.P., Large C., Robertson G., Thomas P., Lewell X.Q. Mapping of dopamine D3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system. J. Recept. Signal. Transduct. Res. 1998, 18:133-150.
12. Mach R.H., Huang Y., Freeman R.A., Wu L., Blair S., Luedtke R.R. Synthesis of 2-(5-bromo-2,3-dimethoxyphenyl)-5-(aminomethyl)-1H-pyrrole analogues and their binding affinities for dopamine D2, D3, and D4 receptors. Bioorg. Med. Chem. 2003, 11:225-233.
13. Mansour A., Meng F., Meador-Woodruff J.H., Taylor L.P., Civelli O., Akil H. Site-directed mutagenesis of the human dopamine D2 receptor. Eur. J. Pharmacol. 1992, 227:205-214.
14. McCall R.B., Lookingland K.J., Bedard P.J., Huff R.M. Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease. J. Pharmacol. Exp. Ther. 2005, 314:1248-1256.
15. Munson P.J., Rodbard D. An exact correction to the " Cheng-Prusoff" correction. J. Recept. Res. 1988, 8:533-546.
16. Sartania N., Strange P.G. Role of conserved serine residues in the interaction of agonists with D3 dopamine receptors. J. Neurochem. 1999, 72:2621-2624.
17. Saur O., Hackling A.E., Perachon S., Schwartz J.C., Sokoloff P., Stark H. N-(4-(4-(2-Halogenophenyl)piperazin-1-yl)butyl) substituted cinnamoyl amide derivatives as dopamine D2 and D3 receptor ligands. Arch. Pharm. (Weinheim) 2007, 340:178-184.
18. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347:146-151.
19. Sokoloff P., Martres M.P., Giros B., Bouthenet M.L., Schwartz J.C. The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem. Pharmacol. 1992, 43:659-666.
20. Strange P.G. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev. 2001, 53:119-133.
21. Strange P.G. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol. Sci. 2008, 29:314-321.
22. Tomlinson G. Potential misconceptions arising from the application of enzyme kinetic equations to ligand-receptor systems at equilibrium. Can. J. Physiol. Pharmacol. 1988, 66:342-349.
23. Watts V.J., Wiens B.L., Cumbay M.G., Vu M.N., Neve R.L., Neve K.A. Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells. J. Neurosci. 1998, 18:8692-8699.
24. Werner P., Hussy N., Buell G., Jones K.A., North R.A. D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes. Mol. Pharmacol. 1996, 49:656-661.
25. Zaworski P.G., Alberts G.L., Pregenzer J.F., Im W.B., Slightom J.L., Gill G.S. Efficient functional coupling of the human D3 dopamine receptor to G(o) subtype of G proteins in SH-SY5Y cells. Br. J. Pharmacol. 1999, 128:1181-1188.
26. Zhen J., Maiti S., Chen N., Dutta A.K., Reith M.E. Interaction between a hydroxypiperidine analogue of 4-(2-benzhydryloxy-ethyl)-1-(4-fluorobenzyl)piperidine and Aspartate 68 in the human dopamine transporter. Eur. J. Pharmacol. 2004, 506:17-26.